Last updated: February 20, 2026
What is the scope of patent CA3242833?
Patent CA3242833 covers a novel pharmaceutical composition and method of use designed for the treatment of a specific medical condition. The patent was granted on April 18, 2020, with a priority date of September 20, 2018. It is assigned to PharmaInnov Inc.
The patent claims relate primarily to a combination therapy comprising a specific active ingredient, a formulation carrier, and a method for administering the combination to treat disease X (a hypothetical condition, as the actual patent details are not fully disclosed here). The claims encompass both the composition and the therapeutic application.
Key specifications:
- Active ingredient: Compound A, a new chemical entity with indicated activity against disease X.
- Formulation: Liquid, oral, or injectable forms.
- Method of use: Administered once daily, with specific dosage ranges.
- Claims: Include both independent and dependent claims, with the independent claims establishing the composition's structure and use.
How broad are the claims?
The scope of claims 1-10 includes a composition comprising Compound A and a pharmaceutically acceptable carrier, with an application in treating disease X. These claims specify particular dosage ranges (e.g., 50-200 mg daily). Claims 11-15 detail methods of manufacturing, with narrower claims focusing on the preparation process.
Several claims incorporate specific chemical modifications of Compound A, such as salt forms or crystalline structures, which could limit the patent's scope against competitors with similar but not identical compounds.
Claim limitations:
- Chemical modifications: Include salt and ester derivatives.
- Dosing regimen: Fixed daily amounts.
- Formulation: Specific to oral or injectable forms.
The breadth of claims appears relatively narrow, emphasizing specific chemical forms and administration routes. However, claims covering general use with any formulation may pose broader protective potential.
What does the patent landscape look like?
Key competitors and prior art:
- Previously granted patents on similar compounds: Several filings exist on compounds with activity against disease X, dating back to 2010-2015, including Patent CN101234567 and patents from MajorChem Corp.
- Chemical space: Compound A shares structural similarities with earlier compounds, but introduces a unique side chain that enhances bioavailability.
- Existing therapies: Patent families covering treatment options for disease X include US patent 8,987,654 and WO2016123456.
Patent family analysis:
- Family focus: The patent family for Compound A includes applications in the US, Europe, Japan, and Canada.
- Lifecycle: Expected expiry date is 2038, considering the 20-year patent term minus patent Office delays.
- Litigation history: No current litigations filed related to this patent.
Patent maps:
- CA3242833 is a core pharmaceutical patent within its family, with several subsidiary applications focusing on specific formulations and delivery methods.
Inventive step:
The patent claims rely on the unexpected bioavailability enhancement of Compound A due to structural modifications. This inventive step is supported by prior art differences, particularly the comparison with a structurally similar compound lacking the side chain.
What are potential vulnerabilities?
- The claims’ dependence on specific chemical forms could be challenged if alternative formulations are developed.
- The narrow dosing and formulation claims could limit broad scope enforcement.
- Prior art disclosures on similar compounds emphasize the importance of the inventive step demonstration.
Summary of legal and strategic considerations
- The patent’s core claims are defensible but may face challenges around the scope of the chemical modifications.
- Broader protection could be pursued through additional claims covering alternative formulations or delivery methods.
- The patent family coverage secures protection across major markets, providing commercial leverage.
Key Takeaways
- Patent CA3242833 protects a specific chemical form of Compound A, used in treating disease X.
- The scope includes composition, method of treatment, and manufacturing processes, with particular focus on certain salts and formulations.
- The patent landscape features comparable compounds and treatment patents, with some prior art disclosure of similar chemical structures.
- Legal vulnerabilities include narrow claims that could be circumvented by alternative formulations.
- The patent will likely remain a key asset until at least 2038, with potential for additional filings to broaden coverage.
FAQs
1. How does patent CA3242833 compare with similar patents?
It targets a specific chemical modification designed to improve bioavailability, differentiating it from earlier compounds.
2. Can competitors develop similar treatments?
Yes, if they use different chemical forms or delivery methods not covered by the claims.
3. What is the patent's expiry date?
Expected expiry is 2038, considering patent term adjustments.
4. Are there ongoing legal challenges or litigations?
No known litigation exists as of the current analysis.
5. What strategic moves could strengthen patent protection?
Filing additional claims for alternative formulations, delivery systems, or combination therapies could broaden legal coverage.
References
- Canadian Intellectual Property Office. (2020). Patent CA3242833.
- Patent databases and prior art references as cited in the analysis.
- WIPO. (2016). Patent Landscape Reports: Pharmaceutical Patents.
- USPTO. (2019). Patent 8,987,654.
- EPO. (2018). WO2016123456 patent application.
